BELI(E)VE protocol evaluates belantamab mafodotin plus venetoclax in t(11;14)-positive relapsed or refractory multiple myeloma
The BELI(E)VE protocol describes a German phase I/IIa trial of belantamab mafodotin plus venetoclax, with or without dexamethasone, in t(11;14)-positive ...
